Fingolimod failure in progressive MS INFORMS future trials

被引：0
|
作者：
Andrew L. Smith
Jeffrey A. Cohen
机构：
[1] Mellen Center for Multiple Sclerosis Treatment and Research in the Neurological Institute,
[2] Cleveland Clinic,undefined
来源：
Nature Reviews Neurology | 2016年 / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Fingolimod is approved for the treatment of relapsing–remitting multiple sclerosis (MS), and evidence suggests that it has neuroprotective effects. The recent INFORMS phase III trial in primary progressive MS demonstrated no beneficial effects of fingolimod on disability progression or whole-brain atrophy, but provides important information for future therapeutic development.
引用
收藏
页码：253 / 254
页数：1
相关论文
共 50 条
  • [41] Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure
    Mansoor, Taha
    Khalid, Subaina N.
    Bilal, Muhammad Ibraiz
    Ijaz, Sardar Hassan
    Fudim, Marat
    Greene, Stephen J.
    Warraich, Haider J.
    Nambi, Vijay
    Virani, Salim S.
    Fonarow, Gregg C.
    Abramov, Dmitry
    Minhas, Abdul Mannan Khan
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2024, : 481 - 504
  • [42] Addressing the Heterogeneity of Heart Failure in Future Randomized Trials
    Iorio A.
    Pozzi A.
    Senni M.
    Current Heart Failure Reports, 2017, 14 (3) : 197 - 202
  • [43] Progressive multiple sclerosis 3 Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives
    Ontaneda, Daniel
    Fox, Robert J.
    Chataway, Jeremy
    LANCET NEUROLOGY, 2015, 14 (02): : 208 - 223
  • [44] Immunological Effects by Longterm Fingolimod Therapy in MS
    Sehr, Tony
    Hainke, Undine
    Zendzian-Piotrowska, Malgorzata
    Bucki, Robert
    Ziemssen, Tjalf
    NEUROLOGY, 2013, 80
  • [45] Fingolimod in MS: special reference to Asian patients
    Matsui, Makoto
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 905 - 905
  • [46] Fingolimod withdrawalRelapse in primary progressive multiple sclerosis after fingolimod withdrawal: 2 case reports
    Reactions Weekly, 2016, 1614 (1) : 84 - 84
  • [47] Cerebral toxoplasmosis in an MS patient receiving Fingolimod
    Enriquez-Marulanda, Alejandro
    Valderrama-Chaparro, Jaime
    Parrado, Laura
    Diego Velez, Juan
    Maria Granados, Ana
    Luis Orozco, Jorge
    Quinones, Jairo
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 18 : 106 - 108
  • [48] BRAIN VOLUME CHANGE AND DISABILITY IN FINGOLIMOD TRIALS
    Nicholas, Richard
    Barkhof, Frederik
    Cohen, Jeffrey
    Radue, Ernst-Willhelm
    Kappos, Ludwig
    Haering, Dieter
    Sfikas, Nikolaos
    von Rosenstiel, Philipp
    Francis, Gordon
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (10):
  • [49] NMDA Receptor Encephalitis in an MS Patient on Fingolimod
    Farber, Rebecca Straus
    Zakin, Elina
    Miller, Aaron
    NEUROLOGY, 2016, 86
  • [50] Ventricular arrhythmia in a male MS patient on fingolimod
    Vincent van Pesch
    Sébastien Marchandise
    Souraya El Sankari
    Christian Sindic
    Acta Neurologica Belgica, 2015, 115 : 77 - 79
12345